Breast
Two RT-planning questions: how much margin matters when every pt gets whole-breast irradiation, and which cardiac dose metric to constrain to now that mean heart dose is uniformly low.
NSABP B-35 margin-width analysis
ForPostmenopausal HR+ DCIS after lumpectomy, WBI and 5yr endocrine therapy
5.6% vs 4.0%
1mm cutoff, absolute difference 1.6%; 2mm cutoff 5.3% vs 3.8%
TL;DR10yr IBTR 5.6% vs 4.0% at 1mm cutoff (abs diff 1.6%), 5.3% vs 3.8% at 2mm (abs diff 1.5%).
Reported via The ASCO Post →
The RT-relevant read is that every patient here got whole-breast irradiation plus 5 years of endocrine therapy, so the 1.5% to 1.6% margin penalty is the residual after full adjuvant treatment. That gates transfer: it says nothing about a close margin when RT is omitted or refused, which is where the margin question actually bites.
In a postmenopausal woman with HR+ DCIS whose lumpectomy margin is under 2mm and who will complete whole-breast RT plus 5yr endocrine therapy, this argues re-excision buys little; it does not extend to premenopausal, HR-negative, or RT-omitted pts.
Every patient here received whole-breast irradiation with an optional boost plus 5yr endocrine therapy, so 1.5% to 1.6% is the residual margin effect after full adjuvant treatment. Boost use by margin group is not reported in source, which matters: it determines whether a close margin was tolerated or quietly compensated.
A margin under 2mm carried a 10yr IBTR of 5.3% vs 3.8% for ≥2mm, an absolute 1.5% penalty, in the largest randomised-trial population yet examined. That directly gates the return-to-theatre decision, though margin width was not randomised and the narrow group is enriched for disease that could not be cleared.
9 details 1 trial watching
Secondary margin-width analysis of NRG Oncology/NSABP B-35, a double-blind randomised trial of tamoxifen vs anastrozole that enrolled 3,104 postmenopausal women 2003-2006. Because local recurrence did not differ between the two endocrine arms, the arms were pooled and margin width analysed across the whole population. Margin data were collected prospectively by participating pathologists.
Postmenopausal women with hormone receptor-positive DCIS treated with lumpectomy. Two overlapping analysis cohorts: n=2,707 with margins classifiable as <1mm (close/indefinite) vs ≥1mm, and n=2,546 with the closest margin measured, permitting a <2mm vs ≥2mm cutoff.
All patients received whole-breast irradiation with an optional boost. Dose, fractionation and boost uptake are not reported in the source, so the RT exposure behind these recurrence rates cannot be characterised beyond "whole breast, boost optional".
Primary endpoint of interest: cumulative incidence of ipsilateral breast tumor recurrence at 10 years, analysed at both the 1mm and 2mm cutoffs. A secondary analysis of all breast cancer events, including contralateral disease, was also performed.
The prevailing 2mm threshold rests largely on the SSO/ASTRO/ASCO DCIS consensus, whose meta-analytic base drew heavily on series with variable and often absent adjuvant therapy. This analysis puts the same question to a uniformly irradiated, uniformly endocrine-treated randomised trial population, which is why the residual margin effect looks so much smaller.
Margin width was not randomised, and patients re-excised on trial carry their final margin, so the narrow-margin group is enriched for disease that could not be cleared. Source reports no hazard ratios, confidence intervals or event counts, and no multivariable adjustment for grade, size, age or boost use.
The claim is that a 1.5% to 1.6% absolute 10-year difference does not justify routine reoperation, which is a value judgment about the trade against anxiety, cosmesis and cost rather than a statistical one. The difference was statistically significant at the 1mm cutoff, so the argument turns on clinical meaningfulness, and a patient who weighs local recurrence heavily could reasonably read the same number differently.
| Cutoff | Narrow margin | Wider margin | Absolute difference |
|---|---|---|---|
| 1 mm | 5.6% (n=502) | 4.0% (n=2,205) | 1.6% |
| 2 mm | 5.3% (n=879) | 3.8% (n=1,667) | 1.5% |
Prospectively collected margin data from a large RCT population directly contests the 2mm re-excision threshold, but the margin comparison itself is non-randomised and abstract-only.
- Does the finding hold when whole-breast RT is omitted? not yet Assessment of Biosignature Classification of DCIS for RadioTherapy Benefit Post Lumpectomy (ABCD RT) Phase 3n=5270 · primary completion 2039-07 · randomises RT omission in biosignature-low DCIS
- Boost use and dose by margin group
- Applicability to premenopausal or HR-negative DCIS
📚 Sources · 📄 1 paper
Abstract
Cardiac Risk After Heart-Sparing Breast Radiotherapy
ForLeft-sided breast cancer, 3D-CRT or IMRT, 2008-2018
TL;DRMax LAD ≥12 Gy EQD2: sHR 1.81 (1.04-3.16) for cardiac events; mean heart dose ≥2 Gy null (P=.99), 2223 left-sided pts.
The number that reaches the planning system is the physical-dose translation: 12 Gy EQD2 max LAD is about 10.5 Gy at 42.5 Gy/16 fx and 7 Gy at 26 Gy/5 fx. Discrimination was weak for both metrics (C index 0.58 vs 0.53), so this argues for adding an LAD max objective and motion management, not for retiring mean heart dose.
In left-sided breast cancer planned with 3D-CRT or IMRT, this supports carrying an LAD max objective alongside the usual heart constraint; it does not extend to right-sided disease, which sat outside the primary analysis.
The actionable number is the physical-dose translation: 12 Gy EQD2 max LAD is about 10.5 Gy at 42.5 Gy/16 fx and 7 Gy at 26 Gy/5 fx, both checkable at the workstation. Discrimination was weak for both metrics (C index 0.58 vs 0.53), so this adds an LAD max objective and breath-hold rather than retiring the heart constraint.
9 details 4 trials watching
Cross-sectional cohort of 4908 breast cancer pts treated with 3D-CRT or IMRT from 2008 to 2018 at one Canadian tertiary center, 2223 left-sided in the primary analysis. Median follow-up 10.8 years (IQR 8.4-13.1). Dosimetry auto-segmented from planning CT, converted to EQD2; competing-risks (Fine and Gray) regression adjusted for cardiovascular risk factors.
Breast cancer treated with 3-dimensional conformal or intensity-modulated RT, 2008 to 2018, with the primary analysis restricted to left-sided disease. Systemic cardiotoxic exposure (anthracycline, trastuzumab) is not reported in source.
3D-CRT or IMRT across the heart-sparing era; LAD and heart automatically segmented and dose converted to EQD2. The threshold is a max point dose to the LAD, not a mean, and the reference schedules are moderate hypofractionation (42.5 Gy in 16 fx) and ultrahypofractionation (26 Gy in 5 fx).
Adverse cardiac events: MI, or admission / ED visit for unstable angina, arrhythmia, heart failure, pericarditis, myocarditis. Coronary angiography and revascularization captured separately as CAD. Discrimination compared by ROC C index, adjusted association by competing-risks regression.
10-year cumulative incidence of cardiac event or CAD was 5.0% (95% CI 4.1-6.0). Metric-by-metric comparison is in the table above.
| Metric | Max LAD dose | Mean heart dose |
|---|---|---|
| Discrimination (C index) | 0.58 (95% CI 0.52-0.64) | 0.53 (95% CI 0.47-0.60) |
| Adjusted association | ≥12 Gy EQD2: sHR 1.81 (1.04-3.16), P=.04 | ≥2 Gy: not associated, P=.99 |
| Schedule | Physical max LAD dose |
|---|---|
| 42.5 Gy / 16 fx | approx 10.5 Gy |
| 26 Gy / 5 fx | approx 7 Gy |
Current whole-heart constraints descend from population dose-response work on cohorts irradiated when incidental cardiac exposure was far higher (Darby, NEJM 2013), the era in which mean heart dose had usable spread. This is the modern counterpart of those series, and the reversal it reports is what you would expect if heart-sparing planning compressed mean heart dose below its discriminating range. The referenced schedules, 42.5 Gy in 16 fractions and 26 Gy in 5 fractions (FAST-Forward), are current practice, so the dosimetric translation transfers.
The mean heart dose null is hard to separate from restricted range: a 2 Gy dichotomy inside a heart-sparing cohort may not span enough exposure for a gradient to show. The endpoint counts coronary angiography and revascularization, which track ascertainment and access as well as biology. Systemic cardiotoxic exposure is not reported in source, leaving an obvious confounder unaddressed.
The asymmetry that matters is cost: an LAD max objective plus breath-hold usually costs optimization time, not target coverage, so a weak association is enough to justify it, while it would not justify trading away chest wall or nodal coverage. The measurement problem cuts the other way, since a max point dose to a small mobile auto-segmented vessel is among the least reproducible quantities to write into a protocol. Motion management carries the least methodological baggage of the two recommendations: it lowers LAD dose and heart dose together.
Cross-sectional single-center cohort with a cut point derived in the same data; C index 0.58 barely above chance and its interval overlaps mean heart dose's.
- External validation of the 12 Gy EQD2 LAD cut point
- Whether LAD-directed planning prospectively lowers cardiac events n=400 · primary completion 2026-04 · DIBH vs free-breathing cardiac dose, paired plansn=750 · primary completion 2027-12 · IMPT vs IMRT/VMAT, cardiac toxicity endpoint
- Generalizability to regional nodal irradiation and 5-fraction schedules active Postmastecomy Internal Mammary Nodal Irradiation for High-risk Breast Cancer Patients Phase 3n=2400 · primary completion 2025-11 · phase 3 IMN irradiation vs none, n=2400recruiting Ultra-Hypofractionated vs. Hypofractionated Radiation for Node-Positive Breast Cancer Phase 2n=220 · primary completion 2034-04 · randomised ultra-hypofx vs hypofx with nodal RT